{
  "docId": "019dd923-622c-750b-8b9a-ad0811d3e80d",
  "docSlug": "dfcef8f28a20",
  "documentTitle": "Accelerate Diagnostics (AXDX)",
  "authorId": "61_White_Diamond_Research",
  "authorName": "White Diamond Research",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2019-09-16 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 41,
  "pageCount": 41,
  "prevPage": 40,
  "nextPage": null,
  "slideType": "thesis_headline",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 3,
  "notes": "This is a short-seller research note.",
  "elementsJson": [
    "headline_text",
    "paragraph"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-ad0811d3e80d/41",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-ad0811d3e80d",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-ad0811d3e80d.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-ad0811d3e80d#slide-41",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "AXDX shares are overpriced and we expect will be declining 70% down in the next 6-9 month.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-78b4-70ad-b3a2-cba6847d25e4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "downside: 70%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-78b4-70ad-b3a2-ce3f362400cf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.031,
        "w": 0.292,
        "x": 0.354,
        "y": 0.873
      },
      "kind": "other",
      "text": "Copyright 2019 White Diamond Research research@whitediamondresearch.com",
      "attrs": null,
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e39ec4f7-42ba-49b8-8f95-7c5d4c91f981",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.285,
        "w": 0.764,
        "x": 0.118,
        "y": 0.165
      },
      "kind": "paragraph",
      "text": "The pressure is mounting around AXDX. With Mayo-UCLA study likely failing to show reduction in mortality and LOS, lacking NTAP reimbursement, troubling current utilization rates, and management decision to finance risky lease agreements, AXDX will continue to disappoint investors. We believe that AXDX technology is not up to the grandiose task of diagnostic revolution. Pheno's inability to replace cell culture equipment, Pheno's high rate of useless inconclusive data, an overestimated by investors clinical utility of AST, Pheno's unjustified expense over MALDI, and it user unfriendliness will eventually position AXDX as a niche diagnostic play with a fair market value of $ 200M to $ 300M.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76f48cbe-e8ff-4d9c-80b2-188f63418ed1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.141,
        "w": 0.764,
        "x": 0.118,
        "y": 0.093
      },
      "kind": "title",
      "text": "AXDX shares are overpriced and we expect will be declining 70% down in the next 6-9 month.",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "052e1b67-b314-4241-b7da-9613dddc5ee2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 41,
      "from": 30,
      "beatId": "ca57db9c-677e-4ef8-919c-92b1690ee48e",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document implies that the solution is to be cautious of the system's limitations and avoid investment in AXDX, citing a potential decline in AXDX shares.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}